Journal
JOURNAL OF NEUROCHEMISTRY
Volume 102, Issue 4, Pages 1105-1114Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1471-4159.2007.04642.x
Keywords
Akt; cannabinoid receptor; CB1; delta9-tetra-hydrocannabinol; dopamine; GSK-3; rimonabant
Categories
Ask authors/readers for more resources
Delta9-tetrahydrocannabinol (THC), the main psychoactive component in Cannabis sativa preparations, exerts its central effects mainly through the G-protein coupled receptor CB1, a component of the endocannabinoid system. Several in vitro and in vivo studies have reported neuroprotective effects of cannabinoids in excitotoxicity and neurodegeneration models. However, the intraneuronal signaling pathways activated in vivo by THC underlying its central effects remain poorly understood. We report that THC acute administration (10 mg/kg, i.p.) increases the phosphorylation of Akt in mouse hippocampus, striaturn, and cerebellum. This phosphorylation was mediated by CB1 receptors as it was blocked by the selective CB1 antagonist rimonabant. Moreover, PI3K inhibition by wortmannin abrogated THC-induced phosphorylation of Akt, but blockade of extracellular signal-regulated protein kinases by SL327 did not modify this activation/phosphorylation of Akt. Moreover, administration of the cloparninergic D1 (SCH 23390) and D2 (raclopride) receptor antagonists did not block the activation of PI3K/Akt pathway induced in the striaturn by cannabinoid receptor stimulation, suggesting that this effect is independent of the clopaminergic system. In addition, THIC increased the phosphorylation of glycogen synthase kinase 3 beta. Therefore, activation of the PI3K/AkVGSK-3 signaling pathway may be related to the in vivo neuroprotective properties attributed to cannabinoids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available